A phase I study of combination adjuvant immunotherapy with HSP70 derived peptide, GPC3 derived peptide, IMP321 and Hiltonol for patients with resectable hepatocellular carcinoma - A phase I study of combination adjuvant immunotherapy with HSP70 derived peptide, GPC3 derived peptide, IMP321 and Hiltonol for patients with resectable hepatocellular carcinoma

开始日期2018-01-16

申办/合作机构-

JPRN-jRCTs061180058 / Completed临床1期IIT

A phase I study of combination immunotherapy with HSP70 derived peptide, GPC3 derived peptide, IMP321 and Hiltonol for patients with advanced or metastatic solid cancer - A phase I study of combination immunotherapy with HSP70 derived peptide, GPC3 derived peptide, IMP321 and Hiltonol for patients with advanced or metastatic solid cancer

开始日期2016-01-12

申办/合作机构-

100 项与 Anti-GPC3 therapy(Band Therapeutics, LLC) 相关的临床结果

登录后查看更多信息

100 项与 Anti-GPC3 therapy(Band Therapeutics, LLC) 相关的转化医学

登录后查看更多信息

100 项与 Anti-GPC3 therapy(Band Therapeutics, LLC) 相关的专利（医药）

登录后查看更多信息

项与 Anti-GPC3 therapy(Band Therapeutics, LLC) 相关的文献（医药）

2023-03-01·iScience

HMGB1/GPC3 dual targeting vaccine induces dendritic cells-mediated CD8+T cell immune response and elicits potential therapeutic effect in hepatocellular carcinoma

Article

作者: Zheng, Yanyan ; Shi, Xiaoqing ; Zheng, Junnian ; Sobhani, Navid ; Chai, Dafei ; Wang, Jiawei ; Wang, Gang ; Ding, Jiage ; Neeli, Praveen

Hepatocellular carcinoma (HCC) is a fatal malignant tumor, but effective clinical interventions are limited. PLGA/PEI-mediated DNA vaccine encoding the dual targets of high-mobility group box 1 (HMGB1) or GPC3 was developed for HCC treatment. Compared with PLGA/PEI-GPC3 immunization, PLGA/PEI-HMGB1/GPC3 co-immunization significantly inhibited the subcutaneous tumor growth, while increasing the infiltration of CD8⁺T cells and DCs. Furthermore, the PLGA/PEI-HMGB1/GPC3 vaccine induced a strong CTL effect and promoted functional CD8⁺T cell proliferation. Intriguingly, the depletion assay proved that the therapeutic effect PLGA/PEI-HMGB1/GPC3 vaccine was dependent on antigen-specific CD8⁺T cell immune responses. In the rechallenge experiment, PLGA/PEI-HMGB1/GPC3 vaccine provided a long-lasting resistance to the growth of the contralateral tumor by inducing the memory CD8⁺T cell responses. Collectively, PLGA/PEI-HMGB1/GPC3 vaccine could induce a strong and long-lasting CTL effect and inhibit the tumor progression or re-attack. Therefore, the combined co-immunization of PLGA/PEI-HMGB1/GPC3 might be served as an effective anti-tumor strategy against HCC.

2020-11-01·Biopharmaceutics & drug disposition4区 · 医学

A novel semi‐mechanistic tumor growth fraction model for translation of preclinical efficacy of anti‐glypican 3 antibody drug conjugate to human

4区 · 医学

Article

作者: Iyer, Rama ; Kozhich, Alexander ; Vangipuram, Rangan ; Pan, Chin ; Cardarelli, Pina ; Marathe, Punit ; Singh, Renu ; Lee, Francis

Abstract:

The growing fraction (GF) of tumor has been reported as one of the predictive markers of the efficacy of chemotherapeutics. Therefore, a semi‐mechanistic model has been developed that describes tumor growth on the basis of cell cycle, allowing the incorporation of the GF of a tumor in pharmacokinetic/pharmacodynamic (PK/PD) modeling. Efficacy data of anti‐glypican 3 (GPC3) antibody drug conjugate (ADC) in a hepatocellular carcinoma (HCC) patient derived xenograft (PDX) model was used for evaluation of this proposed model. Our model was able to describe the kinetics of growth inhibition of HCC PDX models following treatment with anti‐GPC3 ADC remarkably well. The estimated tumurostatic concentrations were used in tandem with human PKs translated from cynomolgus monkey for prediction of the efficacious dose. The projected efficacious human dose of anti‐GPC3 ADC was in the range 0.20–0.63 mg/kg for the Q3W dosing regimen, with a median dose of 0.50 mg/kg. This publication is the first step in evaluating the applicability of GF in PK/PD modeling of ADCs. The authors are hopeful that incorporation of GF will result in an improved translation of the preclinical efficacy of ADCs to clinical settings and thereby better prediction of the efficacious human dose.

2018-03-01·Medicinal research reviews1区 · 医学

Glypican‐3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment

1区 · 医学

Review

作者: Shang, Wenting ; Tian, Jie ; Yu, Xiaoling ; Zhou, Fubo

Abstract:

Liver cancer is the second leading cause of cancer‐related deaths, and hepatocellular carcinoma (HCC) is the most common type. Therefore, molecular targets are urgently required for the early detection of HCC and the development of novel therapeutic approaches. Glypican‐3 (GPC3), an oncofetal proteoglycan anchored to the cell membrane, is normally detected in the fetal liver but not in the healthy adult liver. However, in HCC patients, GPC3 is overexpressed at both the gene and protein levels, and its expression predicts a poor prognosis. Mechanistic studies have revealed that GPC3 functions in HCC progression by binding to molecules such as Wnt signaling proteins and growth factors. Moreover, GPC3 has been used as a target for molecular imaging and therapeutic intervention in HCC. To date, GPC3‐targeted magnetic resonance imaging, positron emission tomography, and near‐infrared imaging have been investigated for early HCC detection, and various immunotherapeutic protocols targeting GPC3 have been developed, including the use of humanized anti‐GPC3 cytotoxic antibodies, treatment with peptide/DNA vaccines, immunotoxin therapies, and genetic therapies. In this review, we summarize the current knowledge regarding the structure, function, and biology of GPC3 with a focus on its clinical potential as a diagnostic molecule and a therapeutic target in HCC immunotherapy.

项与 Anti-GPC3 therapy(Band Therapeutics, LLC) 相关的新闻（医药）

2023-04-25

·医药笔记

AACR：ADC创新层出不穷，中国药企扮演重要角色

▎ArmstrongAACR已经落幕，本文梳理ADC领域的报告。Seagen此前以26亿美元引进荣昌生物的HER2 ADC新药纬迪西妥单抗，此次AACR报告了临床前研究数据，与Tucatinib联合有治疗HER2阳性、HER2低表达的乳腺癌、胃癌的潜力。Seagen汇报了整合素β6 ADC新药 B6A的临床前数据，其能诱导免疫激活而杀伤细胞，带来一种额外的杀伤机制。Seagen同时汇报了期ISAC技术平台，抗体偶联TLR7/8激动剂。第一三共汇报了Trop2 ADC的临床前数据，包括与PD-1联用的潜力，以及HER3 ADC等的数据。宜联生物报告了HER3 ADC新药YL202的临床前数据。宜联生物同时介绍了其TMALIN技术平台，采用了高度亲水linker，偶联极度稳定，但在肿瘤组织可以选择性释放毒素。阿斯利康披露了FRα ADC新药AZD5335的临床前数据，对FRα低表达或高表达卵巢癌均体现出治疗潜力。阿斯利康披露了B7-H4 ADC的临床前研究数据。阿斯利康汇报了EGFR/cMET双抗ADC的临床前数据。恒瑞医药汇报了HER2 ADC新药SHR-A1811、Trop2 ADC新药SHR-A1921的早期临床数据和临床前数据。Zymeworks汇报了NaPi2b ADC、FRα ADC、GPC3 ADC的临床前数据。Bioatla报告了Nectin-4 ADC的临床前数据，在其条件激活抗体CAB技术平台上构建。启德医药报告了HER2 ADC、Trop2 ADC新药GQ1010的临床前数据。ADCT Therapeutics汇报了IL13RA2 ADC新药ADCT-211的临床前数据，PSMA ADC新药ADCT-212，采用PBD毒素。武田报告了免疫刺激型ADC技术平台上开发的CCR2 ADC，采用STING激动剂作为payload。Seven and Eight报告了PD-L1 ADC的临床前数据，payload为TLR7/8激动剂。礼新医药汇报了IL-13RA2 ADC新药LM-306的临床前数据。映恩生物汇报了HER2 ADC、HER3 ADC新药的临床前数据以及HER3 ADC的临床方案。百力司康汇报了HER2 ADC新药BB-1701的临床前数据。普方生物汇报了FRα ADC新药PRO1184的临床前数据以及临床方案。百利药业报告了EGFR/HER3 ADC、HER2 ADC、Trop2 ADC的临床前数据。新加坡Hummingbird Bio汇报了HER3 ADC的临床前数据。加科思汇报了CD73 ADC的临床前数据，payload为STING激动剂。百奥赛图报告了多款双抗ADC的临床前数据，包括HER2/Trop2 ADC、EGFR/cMET ADC、HER3/MET ADC、5T4/MET ADC、HER3/MUC1 ADC、Trop2/EGFR ADC、PTK7/Trop2 ADC、EGFR/MUC1 ADC等。Ambrx汇报了CD70 ADC的临床前数据、PSMA ADC的一期临床方案。康源久远汇报了HER2双抗ADC的临床前数据。赛诺菲汇报了CEACAM5 ADC的临床前数据。Mersana汇报HER2 ADC新药XMT-2056的临床前数据。博锐生物汇报了ROR1双表位双抗ADC的临床前数据。Sutro汇报了ROR1 ADC的临床前数据。LCB汇报了新靶点ADC的临床前数据。普众发现、昂阔医药汇报了CDH6 ADC的临床前数据。总结今年AACR中国企业的参与远超以往，以ADC为例，超过70%的ADC报告都来自中国药企，涌现出许多差异化设计和探索，比如宜联生物的肿瘤微环境选择性释放毒素、百奥赛图多款双抗ADC等等。过去一年多时间，国内ADC新药和技术完成多项重要海外授权交易，也表明了中国药企在ADC领域扮演越来越重要的角色。Armstrong技术全梳理系列GPRC5D靶点全梳理；CD40靶点全梳理；CD47靶点全梳理；补体靶向药物技术全梳理；补体药物：眼科治疗的重要方向；Claudin 6靶点全梳理；Claudin 18.2靶点全梳理；靶点冷暖，行业自知；中国大分子新药研发格局；被炮轰的“me too”；佐剂百年史；胰岛素百年传奇；CUSBEA：风雨四十载；中国新药研发的焦虑；中国生物医药企业的研发竞争；中国双抗竞争格局；中国ADC竞争格局；中国双抗技术全梳理；中国ADC技术全梳理；Ambrx技术全梳理；Vir Biotech技术全梳理；Immune-Onc技术全梳理；科济药业技术全梳理；恺佧生物技术全梳理；同宜医药技术全梳理；百奥赛图技术全梳理；腾盛博药技术全梳理；创胜集团技术全梳理；永泰生物技术全梳理；中国抗体技术全梳理；德琪医药技术全梳理；德琪医药技术全梳理2.0；和铂医药技术全梳理；荣昌生物技术全梳理；再鼎医药技术全梳理；药明生物技术全梳理；恒瑞医药技术全梳理；豪森药业技术全梳理；正大天晴技术全梳理；吉凯基因技术全梳理；基石药业技术全梳理；百济神州技术全梳理；百济神州技术全梳理第2版；信达生物技术全梳理；信达生物技术全梳理第2版；中山康方技术全梳理；复宏汉霖技术全梳理；先声药业技术全梳理；君实生物技术全梳理；嘉和生物技术全梳理；志道生物技术全梳理；道尔生物技术全梳理；尚健生物技术全梳理；康宁杰瑞技术全梳理；科望医药技术全梳理；科望医药技术全梳理2.0；岸迈生物技术全梳理；礼进生物技术全梳理；康桥资本技术全梳理；余国良的抗体药布局；荃信生物技术全梳理；安源医药技术全梳理；三生国健技术全梳理；仁会生物技术全梳理；乐普生物技术全梳理；同润生物技术全梳理；宜明昂科技术全梳理；派格生物技术全梳理；迈威生物技术全梳理；Momenta技术全梳理；NGM技术全梳理；普米斯生物技术全梳理；普米斯生物技术全梳理2.0；三叶草生物技术全梳理；贝达药业抗体药全梳理；泽璟制药抗体药全梳理；恒瑞医药抗体药全梳理；齐鲁制药抗体药全梳理；石药集团抗体药全梳理；豪森药业抗体药全梳理；华海药业抗体药全梳理；科伦药业抗体药全梳理；百奥泰技术全梳理；凡恩世技术全梳理。

抗体药物偶联物AACR会议临床结果临床1期

100 项与 Anti-GPC3 therapy(Band Therapeutics, LLC) 相关的药物交易

登录后查看更多信息